Physician profile
Benjamin C Bryson
NPI 1184887432
$7,642.50
in general payments reported to CMS, 2019-2025
30 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $1,206 · 2021: $1,207 · 2022: $1,248 · 2023: $957 · 2024: $1,035 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,913 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.76 |
| Education | $193.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,202.49 | 2019-2025 | Linzess, Creon, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,671.34 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $713.95 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $466.99 | 2019-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $248.49 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $232.17 | 2020-2023 | |
| Qol Medical, LLC | $180.43 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $127.11 | 2022-2025 | Dupixent |
| Genzyme Corporation | $88.57 | 2022-2025 | |
| Evoke Pharma, INC. | $83.43 | 2021-2022 | |
| Gilead Sciences, INC. | $78.94 | 2019-2025 | |
| Pfizer INC. | $67.30 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $63.43 | 2019-2020 | |
| Ucb, INC. | $61.85 | 2019-2020 | |
| Ambu INC. | $51.25 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $42.43 | 2024-2025 | Zenpep |
| Romark Laboratories, Lc | $28.93 | 2019-2020 | |
| Redhill Biopharma INC. | $27.76 | 2020 | |
| Ferring Pharmaceuticals INC. | $24.58 | 2019 | |
| Ardelyx, INC. | $24.50 | 2025 | Ibsrela |
| Mylan Institutional INC. | $24.24 | 2023 | Hulio |
| Medtronic, INC. | $22.62 | 2024 | Gi Genius |
| Intercept Pharmaceuticals, INC. | $17.86 | 2020 | |
| Novo Nordisk INC | $16.15 | 2025 | Wegovy |
| Horizon Therapeutics Plc | $15.40 | 2022 | |
| Celgene Corporation | $14.98 | 2023 | Zeposia |
| Fresenius Kabi USA, LLC | $13.26 | 2023 | Idacio |
| Shionogi INC | $11.82 | 2019 | |
| Allergan, INC. | $10.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Bryson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.